Actively Recruiting
Phase I Study of LUCAR-G39D Cell Therapy Targeting CD19CD20 in Adults With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2024-11-06
33
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating LUCAR-G39D, a dual-targeted cell therapy aimed at CD19 and CD20, in adults aged 18 to 75 with relapsed or refractory B-cell non-Hodgkin lymphoma. This phase I, open-label study focuses on assessing the safety, tolerability, and effectiveness of this treatment in patients who have not responded to previous therapies or have relapsed after multiple treatment lines. Participants will receive a single infusion of LUCAR-G39D cells following a preparatory chemotherapy regimen with cyclophosphamide and fludarabine to reduce immune cells before treatment. The study includes several phases screening, pre-treatment with chemotherapy, treatment with the cell infusion, and follow-up to monitor ongoing effects. During the study, participants will undergo various assessments including monitoring for treatment-related side effects, blood and bone marrow tests to track how the therapy behaves in the body, and evaluations of tumor response and survival outcomes over an average of two years. The study team will also assess immune responses to the therapy and determine the best dose for future studies.
CONDITIONS
Brief Title
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Research Team
H
Huilai Zhang
K
Kaiyang Ding
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
